Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-17-0554
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination With Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer

Cancer Research
Cancer ResearchOncology
2019English

LY3009120, a panRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer

Oncotarget
Oncology
2016English

Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer

2019English

KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

ISO-66, a Novel Inhibitor of Macrophage Migration Inhibitory Factor, Shows Efficacy in Melanoma and Colon Cancer Models

International Journal of Oncology
Cancer ResearchOncology
2014English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

Mechanisms of Endocrine Resistance and Novel Therapeutic Strategies in Breast Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2005English

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Cell Reports
BiochemistryGeneticsMolecular Biology
2017English

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/P53 Mutant Lung Cancer

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy